Lilly adds another sales channel for obesity drug Zepbound
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment,” said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.
Obesity rates are down. Is that because of weight-loss drugs?
In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the NHANES results found two instances of slight decreases in obesity rates and two dips in severe obesity rates. These falls were followed by steady increases in both categories.
Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of ...
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
A Boulder-based company that is developing a orally-delivered drug for obesity and metabolic disorders just reached $25M in ...
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...
The latest in health news includes Zealand Pharma's obesity drug trial, a record dengue outbreak in the Americas, CervoMed's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback